Pain management with opioid analgesics: Balancing risk & benefit

American Journal of Physical Medicine and Rehabilitation

Volumn 88, Issue 3 SUPPL. 2, 2009, Pages

  Stanos, Steven P ^a   Fishbain, David A ^a   Fishman, Scott M ^a  

^a APAC Centers for Pain Management   (United States)

Author keywords

Chronic pain; Drug abuse; Opioid analgesics; Pain management

Indexed keywords

BUPRENORPHINE; CODEINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; MORPHINE SULFATE; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; OPANA; OXYCODONE; OXYMORPHONE; PARACETAMOL; PETHIDINE; PLACEBO; SUFENTANIL; TRAMADOL; UNCLASSIFIED DRUG;

ADDICTION; ANALGESIA; BACKACHE; BEHAVIOR; CHRONIC PAIN; CLINICAL MEDICINE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DEPRESSION; DROWSINESS; DRUG ABUSE; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MISUSE; DRUG SURVEILLANCE PROGRAM; ENVIRONMENT; FIBROMYALGIA; FUNCTIONAL DISEASE; GENETIC POLYMORPHISM; HEALTH CARE; HEALTH CARE POLICY; HUMAN; HYPERALGESIA; KINESIOTHERAPY; LOW BACK PAIN; MONITORING; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYOCLONUS; NAUSEA; NERVE BLOCK; NEUROPATHIC PAIN; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PAIN; PATIENT ASSESSMENT; PHYSICIAN; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRURITUS; PUBLIC HEALTH PROBLEM; REVIEW; RHEUMATOID ARTHRITIS; RISK; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SCIENCE; SCREENING; SOMNOLENCE; UNITED STATES; URINALYSIS; WITHDRAWAL SYNDROME;

EID: 62549132714     PISSN: 08949115     EISSN: None     Source Type: Journal    
DOI: 10.1097/PHM.0b013e318198dcf7     Document Type: Review

References (247)

1. Kuehn BM: Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA 2007;297:249-51
2. Hays L, Kirsh KL, Passik SD: Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky. J Natl Compr Canc Netw 2003;423-8
3. Kalb C: The great back pain debate. Newsweek 2004;143:42-9
4. Tyre P: Medical missteps. Newsweek, Newsweek Web Exclusive 2007 January 6
5. Rosenberg D: Kentucky's pain. Newsweek 2004;144:44-5
6. Compton WM, Volkow ND: Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006;83:S4-7
7. Kuehn BM: Many teens abusing medications. JAMA 2007;297:578-80
8. Claxton M, Schrade B: Prescription-drug deaths soar in state. Medicine fatalities rival murder numbers. The Tennessean 2007 Apr 1
9. Passik SD, Heit H, Kirsh KL: Reality and responsibility: a commentary on the treatment of pain and suffering in a drug-using society. J Opioid Manag 2006;2:123-7
10. Zacny J, Bigelow G, Compton P, et al: College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 2003;69:215-32
11. Paulozzi LJ, Budnitz DS, Xi Y: Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006;15:618-27
12. Fishman SM: Commentary in response to Paulozzi et al.: prescription drug abuse and safe pain management. Pharmacoepidemiol Drug Saf 2006;15:628-31
13. Miller NS: Failure of enforcement controlled substance laws in health policy for prescribing opiate medications: a painful assessment of morbidity and mortality. Am J Ther 2006;13:527-33
14. Rosenblum A, Parrino M, Schnell SH, et al: Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend 2007;90:64-71
15. Joranson DE, Gilson AM: Wanted: a public health approach to prescription opioid abuse and diversion. Pharmacoepidemiol Drug Saf 2006;15:632-4
16. Chan KT, Fishman SM: Legal aspects of chronic opioid therapy. Curr Pain Headache Rep 2006;10:426-30
17. Fishman SM: From balanced pain care to drug trafficking: the case of Dr. William Hurwitz and the DEA. Pain Med 2005;6:162-4
18. Fishman SM: Trust and pharmaco-vigilance in pain medicine. Pain Med 2005;6:392
19. Hoffmann DE, Tarzian AJ: Achieving the right balance in oversight of physician opioid prescribing for pain: the role of state medical boards. J Law Med Ethics 2003;31:21-40
20. Tucker KL: The debate on elder abuse for undertreated pain. Medico-legal case report and commentary: Inadequate pain management in the context of terminal cancer. The case of Lester Tomlinson. Pain Med 2004;5:214-7
21. Furrow BR: Pain management and provider liability: no more excuses. J Law Med Ethics 2001;29:28-51
22. Pain & Policy Studies Group: Achieving Balance in State Pain Policy: A Progress Report Card. Second edition. University of Wisconsin Comprehensive Cancer Center. Madison, Wisconsin. http://www.painpolicy.wisc.edu/ Achieving_Balance/PRC2006.pdf
23. ABC News/USA Today/Stanford University Medical Center Poll: Pain. Broad experience with pain sparks a search for relief. Available at: http://www.abcnews.go.com/images/Politics/979alTheFightAgainstPain. pdf. 2005
24. Stewart WF, Ricci JA, Chee E, et al: Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290:2443-54
25. Krueger AB, Stone AA: Assessment of pain: a community-based diary survey in the USA. Lancet 2008;371:1519-25
26. Substance Abuse and Mental Health Services Administration OoAS: Drug Abuse Warning Network, 2005: National Estimates of Drug-Related Emergency Department Visits. DAWN Series: D-29, DHHS Publication No. (SMA) 07-4256, Rockville, MD. 2007
27. Hughes AA, Bogdan GM, Dart RC: Active surveillance of abused and misused prescription opioids using poison center data: a pilot study and descriptive comparison. Clin Toxicol (Phila) 2007;45:144-51
28. National Drug Intelligence Center USDoJ: National Drug Threat Assessment 2007. Johnstown, PA, National Drug Intelligence Center, U.S. Department of Justice, 2007
29. Cicero TJ, Dart RC, Inciardi JA, et al: The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). Pain Med 2007;8:157-70
30. Substance Abuse and Mental Health Services Administration: Results from the 2007 National Survey on Drug Use and Health. National Findings. Office of Applied Studies, NSDUH Series: H-34, DHHS Publication No. SMA 08-4343. Rockville, MD. 2008
31. The National Center on Addiction and Substance Abuse at Columbia University: Under the Counter: The Diversion and Abuse of Controlled Prescription Drugs in the U.S. New York, NY, The National Center on Addiction and Substance Abuse at Columbia University, 2005
32. Johnston LD, O'Malley PM, Backman JG, et al: Monitoring the Future: National Results on Adolescent Drug Use. Overview of Key Findings, 2007. NIH Publication No. 08-6418. Bethesda, MD, U.S. Department of Health and Human Services. National Institute on Drug Abuse, 2008
33. The National Center on Addiction and Substance Abuse at Columbia University: Wasting the Best and the Brightest: Substance Abuse at America's Colleges and Universities. New York, NY, The National Center on Addiction and Substance Abuse at Columbia University, 2007
34. Substance Abuse and Mental Health Services Administration: Results from the 2006 National Survey on Drug Use and Health. National Findings. Office of Applied Studies, NSDUH Series: H-32, DHHS Publication No. SMA 07-4293. Rockville, MD. 2007
35. Fishbain DA, Cole B, Lewis J, et al: What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008;9:444-59
36. Savage SR, Joranson DE, Covington EC, et al: De-initions related to the medical use of opioids: evolution towards universal agreement. J Pain Symptom Manage 2003;26:655-67
37. Savage S, Covington E, Heit H, et al: A consensus document from American Academy of Pain Medicine, American Pain Society, and American Society of Addiction Medicine. Definitions Related to the Use of Opioids for the Treatment of Pain. American Pain Society, 2001
38. Katz NP, Adams EH, Chilcoat H, et al: Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007;23:648-60
39. Weissman DE, Haddox JD: Opioid pseudoaddiction - an iatrogenic syndrome. Pain 1989;36:363-6
40. Volkow ND, Fowler JS, Wang GJ, et al: Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004;9:557-69.
41. Baler RD, Volkow ND: Drug addiction: the neurobiology of disrupted self-control. Trends Mol Med 2006;12:559-66
42. Cami J, Farre M: Drug addiction. N Engl J Med 2003;349:975-86
43. Brookoff D: Abuse potential of various opioid medications. J Gen Intern Med 1993;8:688-90
44. Butler SF, Benoit CM, Budman SH, et al: Development and validation of an opioid attractiveness scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J 2006;3:5
45. Passik SD, Hays L, Eisner N, et al: Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother 2006;20:5-13
46. Katz N: Opioids: after thousands of years, still getting to know you. Clin J Pain 2007;23:303-6
47. Cicero TJ, Shores CN, Paradis AG, et al: Source of drugs for prescription opioid analgesic abusers: a role for the internet? Pain Med 2008;9:718-23
48. Gilson AM, Ryan KM, Joranson DE, et al: A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage 2004;28:176-88
49. The White House: National Drug Control Strategy. 2007
50. Joranson DE, Gilson AM: Drug crime is a source of abused pain medications in the United States. J Pain Symptom Manage 2005;30:299-301
51. Brushwood DB, Kimberlin CA: Media coverage of controlled substance diversion through theft or loss. J Am Pharm Assoc (Wash DC) 2004;44:439-44
52. National Drug Intelligence Center USDoJ: National Drug Threat Assessment 2008. Johnstown, PA, National Drug Intelligence Center, U.S. Department of Justice, 2007
53. Jung B, Reidenberg MM: The risk of action by the Drug Enforcement Administration against physicians prescribing opioids for pain. Pain Med 2006;7:353-7
54. Fishman SM: Risk of the view through the keyhole: there is much more to physician reactions to the DEA than the number of formal actions. Pain Med 2006;7:360-2
55. Reidenberg MM, Willis O: Prosecution of physicians for prescribing opioids to patients. Clin Pharmacol Ther 2007;81:903-6
56. Gilson AM, Maurer MA, Joranson DE: State medical board members' beliefs about pain, addiction, and diversion and abuse: a changing regulatory environment. J Pain 2007;8:682-91
57. Hoffmann DE: Can state medical boards adequately respond to reports that physicians are inappropriately prescribing opioids? Clin Pharmacol Ther 2007;81:799-801
58. Jung B, Reidenberg MM: Physicians being deceived. Pain Med 2007;8:433-7
59. Richard J, Reidenberg MM: The risk of disciplinary action by state medical boards against physicians prescribing opioids. J Pain Symptom Manage 2005;29:206-12
60. Goldenbaum DM, Christopher M, Gallagher RM, et al: Physicians charged with opioid analgesic-prescribing offenses. Pain Med 2008;9:737-47
61. Drug Enforcement Administration OoDC: Practitioner's Manual: An Informational Outline of the Controlled Substances Act. Washington, DC, Drug Enforcement Administration, 2006
62. Federation of State Medical Boards of the United States, Inc: Model policy for the use of controlled substances for the treatment of pain. 2004
63. Fishman SM: Responsible Opioid Prescribing: A Physician's Guide. Federation of State Medical Boards of the United States, Inc.: 2007
64. Fleming MF, Balousek SL, Klessig CL, et al: Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain 2007;8:573-82
65. Portenoy RK: Chronic opioid therapy in nonmalignant pain. J Pain Symptom Manage 1990;5:S46-62
66. Nedeljkovic SS, Wasan A, Jamison RN: Assessment of efficacy of long-term opioid therapy in pain patients with substance abuse potential. Clin J Pain 2002;18:S39-51
67. Fishbain DA: Chronic pain and addiction. In: Bosy TZ, Cole BE, editors. Weiner's Pain Management: A Practical Guide for Clinicians. 7th ed. Boca Raton, FL, CRC Press, 2006, pp 117-39
68. American Pain Society: Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 5th ed. Glenview, IL, American Pain Society, 2003
69. American Pain Society: Guideline for the Management of Cancer Pain in Adults and Children. Clin ical Practice Guideline No. 3. Glenview, IL, American Pain Society, 2005
70. Martell BA, O'Connor PG, Kerns RD, et al: Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med 2007;146:116-27
71. Eriksen J, Sjogren P, Bruera E, et al: Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain 2006;125:172-9
72. Furlan AD, Sandoval JA, Mailis-Gagnon A, et al: Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006;174:1589-94
73. Eisenberg E, McNicol ED, Carr DB: Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA 2005;293:3043-52
74. Kalso E, Edwards JE, Moore RA, et al: Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372-80
75. Devulder J, Richarz U, Nataraja SH: Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin 2005;21:1555-68
76. Portenoy RK, Farrar JT, Backonja MM, et al: Long-term use of controlled-release oxycodone for non-cancer pain: results of a 3-year registry study. Clin J Pain 2007;23:287-99
77. Dillie KS, Fleming MF, Mundt MP, et al: Quality of life associated with daily opioid therapy in a primary care chronic pain sample. J Am Board Fam Med 2008;21:108-17
78. Cole BE: Neuroendocrine implications of opioid therapy. Curr Pain Headache Rep 2007;11:89-92
79. Abs R, Verhelst J, Maeyaert J, et al: Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000;85: 2215-22
80. Finch PM, Roberts LJ, Price L, et al: Hypogonadism in patients treated with intrathecal morphine. Clin J Pain 2000;16:251-4
81. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al: Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy. J Pain Symptom Manage 2003;26: 1055-61
82. Roberts LJ, Finch PM, Pullan PT, et al: Sex hormone suppression by intrathecal opioids: a prospective study. Clin J Pain 2002;18:144-8
83. Goldman D, Oroszi G, Ducci F: The genetics of addictions: uncovering the genes. Nat Rev Genet 2005;6:521-32
84. Kreek MJ, Nielsen DA, LaForge KS: Genes associated with addiction: alcoholism, opiate, and cocaine addiction. Neuromolecular Med 2004;5:85-108
85. Kreek MJ: Drug addictions. Molecular and cellular endpoints. Ann N Y Acad Sci 2001;937:27-49
86. Kreek MJ, Nielsen DA, Butelman ER, et al: Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 2005;8:1450-7
87. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al: Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res 2006;6:46
88. Mayer P, Hollt V: Genetic disposition to addictive disorders-current knowledge and future perspectives. Curr Opin Pharmacol 2005;5:4-8
89. Patton GC, Coffey C, Carlin JB, et al: Teen smokers reach their mid twenties. J Adolesc Health 2006;39: 214-20
90. Agrawal A, Grant JD, Waldron M, et al: Risk for initiation of substance use as a function of age of onset of cigarette, alcohol and cannabis use: findings in a Midwestern female twin cohort. Prev Med 2006;43:125-8
91. Ballantyne JC: Opioids for chronic nonterminal pain. South Med J 2006;99:1245-55
92. Passik SD, Webster LR: Pain and addiction interface. Pain Med 2008;9:631-3
93. Edlund MJ, Sullivan M, Steffick D, et al: Do users of regularly prescribed opioids have higher rates of substance use problems than nonusers? Pain Med 2007;8:647-56
94. Compton P: Should opioid abusers be discharged from opioid-analgesic therapy? Pain Med 2008;9: 383-90
95. American Academy of Pain Medicine, American Pain Society: The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and American Pain Society. APS, approved 1996, updated 2006
96. Bair MJ: Overcoming fears, frustrations, and competing demands: an effective integration of pain medicine and primary care to treat complex pain patients. Pain Med 2007;8:544-5
97. Dunbar SA, Katz NP: Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: report of 20 cases. J Pain Symptom Manage 1996;11:163-71
98. Collins ED, Streltzer J: Should opioid analgesics be used in the management of chronic pain in opiate addicts? Am J Addict 2003;12:93-100
99. Kreek MJ, Koob GF: Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend 1998;51:23-47
100. Zacny JP, Lichtor SA: Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. Psychopharmacology (Berl) 2008;196: 105-16
101. Weiner DK, Rudy TE, Morrow L, et al: The relationship between pain, neuropsychological performance, and physical function in community-dwelling older adults with chronic low back pain. Pain Med 2006;7:60-70
102. Heyer EJ, Sharma R, Winfree CJ, et al: Severe pain confounds neuropsychological test performance. J Clin Exp Neuropsychol 2000;22:633-9
103. Brown RT, Zuelsdorff M, Fleming M: Adverse effects and cognitive function among primary care patients taking opioids for chronic nonmalignant pain. J Opioid Manag 2006;2:137-46
104. Apkarian AV, Sosa Y, Krauss BR, et al: Chronic pain patients are impaired on an emotional decision-making task. Pain 2004;108:129-36
105. Jamison RN, Schein JR, Vallow S, et al: Neuropsychological effects of long-term opioid use in chronic pain patients. J Pain Symptom Manage 2003;26:913-21
106. Tassain V, Attal N, Fletcher D, et al: Long term effects of oral sustained release morphine on neuropsychological performance in patients with chronic non-cancer pain. Pain 2003;104:389-400
107. Delgado PL: Common pathways of depression and pain. J Clin Psychiatry 2004;65(Suppl 12):16-9
108. Bair MJ, Robinson RL, Katon W, et al: Depression and pain comorbidity: a literature review. Arch Intern Med 2003;163:2433-45
109. Katona C, Peveler R, Dowrick C, et al: Pain symptoms in depression: definition and clinical significance. Clin Med 2005;5:390-5
110. Sator-Katzenschlager SM, Schiesser AW, Kozek-Langenecker SA, et al: Does pain relief improve pain behavior and mood in chronic pain patients? Anesth Analg 2003;97:791-7
111. Won A, Lapane KL, Vallow S, et al: Long-term effects of analgesics in a population of elderly nursing home residents with persistent nonmalignant pain. J Gerontol A Biol Sci Med Sci 2006;61:165-9
112. Chelminski PR, Ives TJ, Felix KM, et al: A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric Comorbidity. BMC Health Serv Res 2005;5:3
113. Deshpande MA, Holden RR, Gilron I: The impact of therapy on quality of life and mood in neuropathic pain: what is the effect of pain reduction? Anesth Analg 2006;102:1473-9
114. Fishbain DA, Cutler RB, Rosomoff HL, et al: Can patients taking opioids drive safely? A structured evidence-based review. J Pain Palliat Care Pharmacother 2002;16:9-28
115. Fishbain DA, Lewis JE, Cole B, et al: Medicolegal rounds: Medicolegal issues and alleged breaches of standards of medical care in a patient motor vehicle accident allegedly related to chronic opioid analgesic therapy. J Opioid Manag 2007;3: 16-20
116. Fishbain DA, Cutler RB, Rosomoff HL, et al: Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manage 2003;25:559-77
117. Menefee LA, Frank ED, Crerand C, et al: The effects of transdermal fentanyl on driving, cognitive performance, and balance in patients with chronic nonmalignant pain conditions. Pain Med 2004;5: 42-9
118. Gaertner J, Radbruch L, Giesecke T, et al: Assessing cognition and psychomotor function under long-term treatment with controlled release oxycodone in non-cancer pain patients. Acta Anaesthesiol Scand 2006;50:664-72
119. Byas-Smith MG, Chapman SL, Reed B, et al: The effect of opioids on driving and psychomotor performance in patients with chronic pain. Clin J Pain 2005;21:345-52
120. Verster JC, Veldhuijzen DS, Volkerts ER: Effects of an opioid (oxycodone/paracetamol) and an NSAID (bromfenac) on driving ability, memory functioning, psychomotor performance, pupil size, and mood. Clin J Pain 2006;22:499-504
121. Veldhuijzen DS, van Wijck AJ, Wille F, et al: Effect of chronic nonmalignant pain on highway driving performance. Pain 2006;122:28-35
122. Bailey CP, Couch D, Johnson E, et al: Mu-opioid receptor desensitization in mature rat neurons: lack of interaction between DAMGO and morphine. J Neurosci 2003;23:10515-20
123. Bailey CP, Smith FL, Kelly E, et al: How important is protein kinase C in mu-opioid receptor desensitization and morphine tolerance? Trends Pharmacol Sci 2006;27:558-65
124. McIlwain H, Ahdieh H: Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study. Am J Ther 2005;12:106-12
125. Chu LF, Clark DJ, Angst MS: Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006;7:43-8
126. Pud D, Cohen D, Lawental E, et al: Opioids and abnormal pain perception: New evidence from a study of chronic opioid addicts and healthy subjects. Drug Alcohol Depend 2006;82:218-23
127. Mercadante S, Arcuri E: Hyperalgesia and opioid switching. Am J Hasp Palliat Care 2005;22:291-4
128. Mercadante S, Ferrera P, Villari P, et al: Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage 2003;26:769-75
129. Gardell LR, King T, Ossipov MH, et al: Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neurosci Lett 2006;396:44-9
130. Baron MJ, McDonald PW: Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. J Opioid Manag 2006;2: 277-82
131. King T, Ossipov MH, Vanderah TW, et al: Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals 2005;14:194-205
132. Mao J: Opioid-induced abnormal pain sensitivity. Curr Pain Headache Rep 2006;10:67-70
133. Wilson GR, Reisfield GM: Morphine hyperalgesia: a case report. Am J Hosp Palliat Care 2003;20: 459-61
134. Vorobeychik Y, Chen L, Bush MC, et al: Improved opioid analgesic effect following opioid dose reduction. Pain Med 2008;9:724-7
135. Akbik H, Butler SF, Budman SH, et al: Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). J Pain Symptom Manage 2006;32:287-93
136. Webster LR, Webster RM: Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool. Pain Medicine 2005;6:432-42
137. Belgrade MJ, Schamber CD, Lindgren BR: The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain 2006;7:671-81
138. Passik SD, Kirsh KL, Casper D: Addiction-related assessment tools and pain management. Pain Med 2008;9:S145-66
139. Michna E, Ross EL, Hynes WL, et al: Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage 2004;28:250-8
140. Weaver MF, Jarvis MA, Schnell SH: Role of the primary care physician in problems of substance abuse. Arch Intern Med 1999;159:913-24
141. Ewing JA: Detecting alcoholism. The CAGE questionnaire. JAMA 1984;252:1905-7
142. Mayfield D, McLeod G, Hall P: The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry 1974;131: 1121-3
143. Brown RL, Rounds LA: Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice. Wis Med J 1995;94:135-40
144. Skinner HA, Holt S, Schuller R, et al: Identification of alcohol abuse using laboratory tests and a history of trauma. Ann Mem Med 1984;101:847-51
145. O'Brien CP: Drug Addiction and Drug Abuse. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed. Brunton LL, Lazo JS, Parker KL, et al, eds. New York, NY, McGraw-Hill, 2005
146. Fishbain DA: Pharmacotherapeutic management of breakthrough pain in patients with chronic persistent pain. Am J Manag Care 2008;14:S123-8
147. Reder RF: Opioid formulations: tailoring to the needs in chronic pain. Eur J Pain 2001;5:S109-11
148. Menefee Pujol LA, Katz NP, Zacharoff KL: Pain EDU.org Manual. A Pocket Guide to Pain Management, 3rd ed. Newton, MA, Inflexxion Health Series, 2007
149. Nicholson B, Ross E, Weil A, et al: Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules. Curr Med Res Opin 2006;22: 539-50
150. Quigley C: Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004;CD004847
151. Mercadante S, Bruera E: Opioid switching: a systematic and critical review. Cancer Treat Rev 2006;32:304-15
152. Mercadante S: Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 1999;86: 1856-66
153. Ross JR, Riley J, Quigley C, et al: Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist 2006;11:765-73
154. McNicol E, Horowicz-Mehler N, Fisk RA, et al: Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003;4:231-56
155. Drake R, Longworth J, Collins JJ: Opioid rotation in children with cancer. J Palliat Med 2004;7:419-22
156. Riley J, Ross JR, Rutter D, et al: No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer 2006;14:56-64
157. Fredheim OM, Kaasa S, Dale O, et al: Opioid switching from oral slow release morphine to oral methadone may improve pain control in chronic non-malignant pain: a nine-month follow-up study. Palliat Med 2006;20:35-41
158. Anderson R, Saiers JH, Abram S, et al: Accuracy in equianalgesic dosing, conversion dilemmas. J Pain Symptom Manage 2001;21:397-406
159. Ross JR, Rutter D, Welsh K, et al: Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 2005;5:324-36
160. Uhl GR, Sora I, Wang Z: The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A 1999;96:7752-5
161. Ikeda K, Ide S, Han W, et al: How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci 2005;26:311-7
162. Pasternak GW: Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci 2001;22:67-70
163. Corbett AD, Henderson G, McKnight AT, et al: 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol 2006;147: S153-62
164. Waldhoer M, Bartlett SE, Whistler JL: Opioid receptors. Annu Rev Biochem 2004;73:953-90
165. Pasternak GW: Multiple opiate receptors: deja vu all over again. Neuropharmacology 2004;47: S312-23
166. Pasternak GW: Molecular biology of opioid analgesia. J Pain Symptom Manage 2005;29:S2-9
167. Lever JR: PET and SPECT imaging of the opioid system: receptors, radioligands and avenues for drug discovery and development. Curr Pharm Des 2007;13:33-49
168. Maarrawi J, Peyron R, Mertens P, et al: Differential brain opioid receptor availability in central and peripheral neuropathic pain. Pain 2007;127:183-94
169. Waldhoer M, Fong J, Jones RM, et al: A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dinners. Proc Natl Acad Sci U S A 2005;102:9050-5
170. Gupta A, Decaillot FM, Devi LA: Targeting opioid receptor heterodimers: strategies for screening and drug development. AAPS J 2006;8:E153-9
171. Landau R: One size does not fit all: genetic variability of mu-opioid receptor and postoperative morphine consumption. Anesthesiology 2006;105: 235-7
172. Somogyi AA, Barratt DT, Coller JK: Pharmacogenetics of opioids. Clin Pharmacol Ther 2007;81: 429-44
173. Reyes-Gibby CC, Shete S, Rakvag T, et al: Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007;130:25-30
174. Klepstad P, Dale O, Skorpen F, et al: Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand 2005;49:902-8
175. Clayton TA, Lindon JC, Cloarec O, et al: Pharmacometabonomic phenotyping and personalized drug treatment. Nature 2006;440:1073-7
176. Klepstad P, Hilton P, Moen J, et al: Day-to-day variations during clinical drug monitoring of morphine, morphine-3-glucuronide and morphine-6-glucuronide serum concentrations in cancer patients. A prospective observational study. BMC Clin Pharmacol 2004;4:7
177. Lotsch J, Geisslinger G: Relevance of frequent muopioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J 2006;6:200-10
178. Lotsch J, Geisslinger G: Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 2005;11:82-9
179. Mayer P, Hollt V: Pharmacogenetics of opioid receptors and addiction. Pharmacogenet Genomics 2006;16:1-7
180. Kreek MJ, Bart G, Lilly C, et al: Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 2005;57:1-26
181. Armstrong SC, Cozza KL: Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II. Psychosomatics 2003;44:515-20
182. Armstrong SC, Cozza KL: Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. Psychosomatics 2003;44:167-71
183. Fine PG, Portenoy RK: A Clinical Guide to Opioid Analgesia. New York, NY, McGraw-Hill, 2004
184. Kirchheiner J, Schmidt H, Tzvetkov M, et al: Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007;7:257-65
185. Susce MT, Murray-Carmichael E, de Leon J: Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1356-8
186. de los Cobos JP, Sinol N, Trujols J, et al: Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug Alcohol Depend 2007;89:190-4
187. Eap CB, Broly F, Mino A, et al: Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol 2001;21:229-34
188. Adams M, Pieniaszek HJ Jr, Gammaitoni AR, et al: Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol 2005;45:337-45
189. Tegeder I, Costigan M, Griffin RS, et al: GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med 2006;12:1269-77
190. Lotsch J, Stuck B, Hummel T: The human muopioid receptor gene polymorphism 118A > G decreases cortical activation in response to specific nociceptive stimulation. Behav Neurosci 2006;120: 1218-24
191. Kim H, Neubert JK, San Miguel A, et al: Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain 2004;109: 488-96
192. Mogil JS: The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proc Natl Acad Sci U S A 1999;96:7744-51
193. Fishbain DA, Cutler RB, Cole B, et al: Medico-legal rounds: medico-legal issues and alleged breaches of "standards of medical care" in opioid rotation to methadone: a case report. Pain Med 2003;4:195-201
194. Zimmermann C, Seccareccia D, Booth CM, et al: Rotation to methadone after opioid dose escalation: How should individualization of dosing occur? J Pain Palliat Care Pharmacother 2005;19:25-31
195. US Food and Drug Administration: Methadone hydrochloride. FDA alert: death, narcotic overdose, and serious cardiac arrhythmias. 2006
196. Webster LR: Methadone-related deaths. J Opioid Manag 2005;1:211-7
197. Gershell L, Goater JJ: Making gains in pain. Nat Rev Drug Discov 2006;5:889-90
198. Gana TJ, Pascual ML, Fleming RR, et al: Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin 2006;22:1391-401
199. Babul N, Noveck R, Chipman H, et al: Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage 2004;28:59-71
200. Wallace MS, Thipphawong J: Clinical trial results with OROS® hydromorphone. J Pain Symptom Manage 2007;33:S25-32
201. Hale M, Tudor IC, Khanna S, et al: Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, openlabel, noninferiority analysis. Clin Ther 2007;29: 874-88
202. Hale ME, Ahdieh H, Ma T, et al: Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain 2007;8:175-84
203. Frommer E: Oxymorphone: a review. Support Care Cancer 2006;14:109-15
204. Katz N, Rauck R, Ahdieh H, et al: A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin 2007;23:117-28
205. Portenoy RK, Taylor D, Messina J, et al: A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805-11
206. Portenoy RK, Messina J, Xie F, et al: Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin 2007;23:223-33
207. Simpson DM, Messina J, Xie F, et al: Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, doubleblind, placebo-controlled study. Clin Ther 2007;29: 588-601
208. Taylor DR: Fentanyl buccal tablet: rapid relief from breakthrough pain. Expert Opin Pharmacother 2007;8:3043-51
209. Durfee S, Messina J, Khankari R: Fentanyl effervescent buccal tablets: enhanced buccal absorption. Am J Drug Delivery 2006;4:1-5
210. Webster LR: Fentanyl buccal tablets. Expert Opin Investis Drugs 2006;15:1469-73
211. Viscusi ER: Emerging treatment modalities: Balancing efficacy and safety. Am J Health Syst Pharm 2007;64:S6-11
212. Sinatra R: The fentanyl HCl patient-controlled transdermal system (PCTS): an alternative to intravenous patient-controlled analgesia in the postoperative setting. Clin Pharmacokinet 2005;44:S1-6
213. Bain KT: A patient-activated iontophoretic transdermal system for acute pain management with fentanyl hydrochloride: overview and applications. J Opioid Manag 2006;2:314-24
214. Viscusi ER, Reynolds L, Tait S, et al: An iontophoretic fentanyl patient-activated analgesic delivery system for postoperative pain: a double-blind, placebo-controlled trial. Anesth Analg 2006;102: 188-94
215. Minkowitz HS, Rathmell JP, Vallow S, et al: Efficacy and safety of the fentanyl iontophoretic transdermal system (ITS) and intravenous patient-controlled analgesia (IV PCA) with morphine for pain management following abdominal or pelvic surgery. Pain Med 2007;8:657-68
216. Webster LR, Butera PG, Moran LV, et al: Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain 2006;7:937-46
217. Webster LR: PTI-821: sustained-release oxycodone using gel-cap technology. Expert Opin Investig Drugs 2007;16:359-66
218. Fudala PJ, Johnson RE: Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend 2006;83:S40-7
219. Lavine G: Abuse deterrence focus of upcoming opioid formulations. Am J Health Syst Pharm 2008;65:381, 385
220. Katz N: Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep 2008;10: 11-8
221. Fishman SM, Mahajan G, Jung SW, et al: The trilateral opioid contract. Bridging the pain clinic and the primary care physician through the opioid contract. J Pain Symptom Manage 2002;24:335-44
222. Gilron I, Watson CP, Cahill CM, et al: Neuropathic pain: a practical guide for the clinician. CMAJ 2006;175:265-75
223. Farrar JT, Young JP Jr, LaMoreaux L, et al: Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58
224. Cleeland CS, Ryan KM: Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38
225. Passik SD, Kirsh KL, Whitcomb L, et al: A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther 2004;26:552-61
226. Passik SD, Kirsh KL: Chronic pain management and substance abuse. Assessing and optimizing outcomes. ElderCare 2002;1-3
227. Passik SD, Kirsh KL: Commentary on Jung and Reidenberg's "Physicians being deceived": aberrant drug-taking behaviors: what pain physicians can know (or should know). Pain Med 2007;8:442-4
228. Kirsh KL, Whitcomb LA, Donaghy K, et al: Abuse and addiction issues in medically ill patients with pain: attempts at clarification of terms and empirical study. Clin J Pain 2002;18:S52-60
229. Passik SD, Kirsh KL: Managing pain in patients with aberrant drug-taking behaviors. J Support Oncol 2005;3:83-6
230. Schnell SH, Weaver MF: Addiction and pain. Am J Addict 2003;12(Suppl 2):S27-35
231. Passik SD: Pain management misstatements: ceiling effects, red and yellow flags. Pain Med 2006;7: 76-7
232. Portenoy RK, Savage SR: Clinical realities and economic considerations: special therapeutic issues in intrathecal therapy-tolerance and addiction. J Pain Symptom Manage 1997;14:S27-35
233. Compton P, Darakjian J, Miotto K: Screening for addiction in patients with chronic pain and "problematic" substance use: evaluation of a pilot assessment tool. J Pain Symptom Manage 1998;16:355-63
234. Lusher J, Elander J, Bevan D, et al: Analgesic addiction and pseudoaddiction in painful chronic illness. Clin J Pain 2006;22:316-24
235. Fishman SM, Bandman TB, Edwards A, et al: The opioid contract in the management of chronic pain. J Pain Symptom Manage 1999;18:27-37
236. Arnold RM, Han PK, Seltzer D: Opioid contracts in chronic nonmalignant pain management: objectives and uncertainties. Am J Med 2006;119:292-6
237. Bolen J: Getting informed consent and agreement for treatment right: a legal perspective on key obligations for practitioners who use controlled substances to treat chronic pain. J Opioid Manag 2006;2:193-200
238. Manchikanti L, Manchukonda R, Damron KS, et al: Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician 2006;9:57-60
239. Fishman SM, Wilsey B, Yang J, et al: Adherence monitoring and drug surveillance in chronic opioid therapy. J Pain Symptom Manage 2000;20: 293-307
240. Roskos SE, Keenum AJ, Newman LM, et al: Literacy demands and formatting characteristics of opioid contracts in chronic nonmalignant pain management. J Pain 2007;8:753-8
241. Becker N, Sjogren P, Bech P, et al: Treatment outcome of chronic non-malignant pain patients managed in a Danish multidisciplinary pain centre compared to general practice: a randomised controlled trial. Pain 2000;84:203-11
242. Michna E, Jamison RN, Pham LD, et al: Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings. Clin J Pain 2007;23:173-9
243. Manchikanti L, Manchukonda R, Pampati V, et al: Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician 2006;9:123-9
244. Gourlay D, Heit HA, Caplan YH: Urine Drug Testing in Clinical Practice: Dispelling the Myths & Designing Strategies. Stamford, CT, PharmaCom Group, Inc, 2006
245. Gourlay DL, Heit HA, Almahrezi A: Universal Precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005;6: 107-112
246. Savage SR: Assessment for addiction in pain-treatment settings. Clin J Pain 2002;18:S28-38
247. Wiedemer NL, Harden PS, Arndt IO, et al: The opioid renewal clinic: a primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Med 2007;8: 573-84